PL371515A1 - Inhibitory hydroksylazy HIF - Google Patents

Inhibitory hydroksylazy HIF

Info

Publication number: PL371515A1
Authority: PL; Poland
Prior art keywords: hydroxylase inhibitors; hif hydroxylase; activity; hif; condition
Prior art date: 2002-03-21

Application number

PL03371515A

Other languages

English (en)

Other versions

PL205110B1 (pl

Inventor

Christopher Joseph Schofield

Patrick Henry Maxwell

Christopher William Pugh

Peter John Ratcliffe

Original Assignee

Isis Innovation Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-21

Filing date

2003-03-21

Publication date

2005-06-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9933457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371515(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-03-21 Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited

2005-06-27 Publication of PL371515A1 publication Critical patent/PL371515A1/pl

2010-03-31 Publication of PL205110B1 publication Critical patent/PL205110B1/pl

Links

102000008109 Mixed Function Oxygenases Human genes 0.000 title 1
108010074633 Mixed Function Oxygenases Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
230000000694 effects Effects 0.000 abstract 2
230000009286 beneficial effect Effects 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Immunology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL371515A 2002-03-21 2003-03-21 Inhibitory hydroksylazy HIF PL205110B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0206711.4A GB0206711D0 (en)	2002-03-21	2002-03-21	HIF Inhibitor

Publications (2)

Publication Number	Publication Date
PL371515A1 true PL371515A1 (pl)	2005-06-27
PL205110B1 PL205110B1 (pl)	2010-03-31

Family

ID=9933457

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL371515A PL205110B1 (pl)	2002-03-21	2003-03-21	Inhibitory hydroksylazy HIF

Country Status (13)

Country	Link
US (2)	US20050227948A1 (pl)
EP (2)	EP1485347B1 (pl)
JP (1)	JP2005520859A (pl)
CN (6)	CN101199502A (pl)
AT (1)	ATE430127T1 (pl)
AU (2)	AU2003216857B2 (pl)
CA (1)	CA2479881A1 (pl)
DE (1)	DE60327428D1 (pl)
ES (1)	ES2322992T3 (pl)
GB (1)	GB0206711D0 (pl)
MX (1)	MXPA04009155A (pl)
PL (1)	PL205110B1 (pl)
WO (1)	WO2003080566A2 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7618940B2 (en)	2002-12-06	2009-11-17	Fibrogen, Inc.	Fat regulation
US8124582B2 (en)	2002-12-06	2012-02-28	Fibrogen, Inc.	Treatment of diabetes
US20050136125A1 (en) *	2003-10-22	2005-06-23	Roth Mark B.	Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20050170019A1 (en) *	2003-10-22	2005-08-04	Fred Hutchinson Cancer Research Center	Methods, compositions and devices for inducing stasis in cells
CN1901795B (zh) *	2003-10-22	2014-03-26	弗雷德哈钦森癌症研究中心	用于在细胞，组织，器官，和有机体中诱导停滞的方法，组合物和装置
WO2005093411A2 (en) *	2004-03-26	2005-10-06	Isis Innovation Limited	Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxigenase and methods of using the same
PL1676591T3 (pl) *	2004-11-24	2018-12-31	Lifescan, Inc.	Kompozycje i sposoby tworzenia unaczynionego środowiska dla przeszczepu komórkowego
CA2605631A1 (en) *	2005-04-20	2006-10-26	Fred Hutchinson Cancer Research Center	Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
DE102005019712A1 (de) *	2005-04-28	2006-11-09	Bayer Healthcare Ag	Dipyridyl-dihydropyrazolone und ihre Verwendung
GB0519605D0 (en)	2005-09-26	2005-11-02	Isis Innovation	Assay
BRPI0707302B8 (pt)	2006-01-27	2021-05-25	Fibrogen Inc	compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
BRPI0710527B8 (pt)	2006-04-04	2021-05-25	Fibrogen Inc	compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
JP2010524935A (ja) *	2007-04-18	2010-07-22	メルク・シャープ・エンド・ドーム・コーポレイション	新規１，８−ナフチリジン化合物
WO2009058403A1 (en) *	2007-11-02	2009-05-07	Fibrogen, Inc.	Methods for reducing blood pressure
WO2009073669A1 (en)	2007-12-03	2009-06-11	Fibrogen, Inc.	Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (en)	2008-01-11	2013-10-09	Fibrogen, Inc.	Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en)	2008-02-05	2009-08-13	Fibrogen, Inc.	Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
WO2009134847A1 (en) *	2008-04-30	2009-11-05	Smithkline Beecham Corporation	Prolyl hydroxylase inhibitors
GB0809262D0 (en)	2008-05-21	2008-06-25	Isis Innovation	Assay
US8217043B2 (en)	2008-08-20	2012-07-10	Fibrogen, Inc.	Compounds and methods for their use
JP5649584B2 (ja)	2008-11-14	2015-01-07	フィブロジェンインコーポレイテッド	Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
CN102959076B (zh)	2010-03-31	2015-09-16	斯克里普斯研究所	重编程细胞
WO2012106472A1 (en)	2011-02-02	2012-08-09	Fibrogen, Inc.	Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
GB201102659D0 (en)	2011-02-15	2011-03-30	Isis Innovation	Assay
GB201113101D0 (en)	2011-07-28	2011-09-14	Isis Innovation	Assay
US9446031B2 (en)	2012-01-18	2016-09-20	National University Of Singapore	Compositions and methods for neovascularization
HK1204977A1 (en) *	2012-03-09	2015-12-11	Fibrogen, Inc.	Treatment for high cholesterol
AU2014209319B2 (en)	2013-01-24	2018-04-19	Fibrogen, Inc.	Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
EP3400003B1 (en) *	2016-01-05	2023-05-03	The Trustees of Columbia University in the City of New York	Compositions for regulating activity of inhibitor of dna binding-2 (id2) protein
WO2018232227A1 (en) *	2017-06-15	2018-12-20	The Trustees Of Columbia University In The City Of New York	Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd
WO2021216530A1 (en)	2020-04-20	2021-10-28	Akebia Therapeutics, Inc.	Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en)	2021-01-08	2022-07-14	Akebia Therapeutics, Inc.	Compounds and composition for the treatment of anemia
EP4347022A1 (en)	2021-05-27	2024-04-10	Keryx Biopharmaceuticals, Inc.	Pediatric formulations of ferric citrate

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1620359A1 (de)	1965-12-10	1969-12-18	Norddeutsche Affinerie	Wachstumbeeinflussende Mittel
AT279048B (de)	1967-07-04	1970-02-25	Pharmazeutische Fabrik Montavit Gmbh	Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon
FR6969M (pl)	1968-05-19	1969-05-19
US4273779A (en) *	1976-12-23	1981-06-16	Ciba-Geigy Corporation	Treating hypertension with substituted-5-amino-2-pyridinecarboxylic acids
JPS5754151A (en) *	1980-09-18	1982-03-31	Takeda Chem Ind Ltd	Physiologically active substance b-52653 and its preparation
JPS5899453A (ja) *	1981-12-10	1983-06-13	Mitsubishi Chem Ind Ltd	オリゴペプチド
US4446038A (en) *	1982-09-27	1984-05-01	Texaco, Inc.	Citric imide acid compositions and lubricants containing the same
US4551279A (en) *	1984-01-09	1985-11-05	G. D. Searle & Co.	Protease inhibitors
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
DE3575144D1 (de)	1984-12-17	1990-02-08	American Cyanamid Co	Platinkomplexe von aliphatischen tricarbonsaeuren.
JPS61218522A (ja)	1985-03-22	1986-09-29	Sachimaru Senoo	中性乃至弱アルカリ性で安定な水酸化鉄コロイド溶液
JPS61249993A (ja)	1985-04-26	1986-11-07	Tanabe Seiyaku Co Ltd	新規有機白金錯体及びその製法
US4752602A (en)	1985-09-09	1988-06-21	Board Of Regents, The University Of Texas System	Dipeptide alkyl esters and their uses
DE3544338A1 (de) *	1985-12-14	1987-06-19	Hoechst Ag	Peptid-derivate mit inhibitorischer wirkung auf hydroxylierende enzyme, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
FR2662359A1 (fr)	1986-04-18	1991-11-29	Flork Michel	Nouveaux peptides diuretiques et natriuretiques.
CH673459A5 (pl)	1987-05-15	1990-03-15	Eprova Ag
DE3818850A1 (de) *	1988-06-03	1989-12-07	Hoechst Ag	Oligopeptide mit zyklischen prolin-analogen aminosaeuren
US5439930A (en)	1992-04-14	1995-08-08	Russian-American Institute For New Drug Development	Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
RU2001588C1 (ru)	1992-05-07	1993-10-30	Феликс Семенович Ройтман	Сок с м котью
JP3595352B2 (ja)	1993-02-01	2004-12-02	株式会社サンギ	抗腫瘍剤及び抗菌剤
DE4410453A1 (de) *	1994-03-25	1995-09-28	Hoechst Ag	Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
WO1997024145A1 (en) *	1995-12-28	1997-07-10	Daiichi Radioisotope Laboratories, Ltd.	Diagnostic drugs
RU2079307C1 (ru)	1996-07-08	1997-05-20	Михаил Александрович Каплан	Противоанемическое средство
RU2111746C1 (ru)	1996-07-31	1998-05-27	Всероссийский научный центр по безопасности биологически активных веществ	Водный раствор, обладающий гепатопротекторным действием
US5972894A (en) *	1997-08-07	1999-10-26	Cytran, Inc.	Peptides having potassium channel opener activity
US6200974B1 (en) *	1997-10-24	2001-03-13	Zeneca Limited	Phenanthroline derivatives
RU2141943C1 (ru)	1998-11-27	1999-11-27	Научно-исследовательский институт фармакологии при Волгоградской медицинской академии	Динатриевая соль n-ацетил-l-аспарагиновой кислоты, обладающая антидепрессантной и ноотропной активностью
US6583299B1 (en)	1999-05-20	2003-06-24	G.D. Searle & Co.	α-amino-β-sulfonyl hydroxamic acid compounds
ATE383877T1 (de) *	1999-06-04	2008-02-15	Dana Farber Cancer Inst Inc	Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren
GB0013655D0 (en)	2000-06-05	2000-07-26	Prolifix Ltd	Therapeutic compounds
JP4590157B2 (ja) *	2001-03-21	2010-12-01	アイシスイノヴェイションリミテッド	アッセイ、方法および手段

2002
- 2002-03-21 GB GBGB0206711.4A patent/GB0206711D0/en not_active Ceased
2003
- 2003-03-21 CN CNA2007103081689A patent/CN101199502A/zh active Pending
- 2003-03-21 JP JP2003578322A patent/JP2005520859A/ja active Pending
- 2003-03-21 EP EP03712396A patent/EP1485347B1/en not_active Revoked
- 2003-03-21 WO PCT/GB2003/001239 patent/WO2003080566A2/en not_active Ceased
- 2003-03-21 AU AU2003216857A patent/AU2003216857B2/en not_active Ceased
- 2003-03-21 CN CNB038109557A patent/CN100369891C/zh not_active Expired - Fee Related
- 2003-03-21 EP EP09001020A patent/EP2065366A3/en not_active Withdrawn
- 2003-03-21 MX MXPA04009155A patent/MXPA04009155A/es active IP Right Grant
- 2003-03-21 ES ES03712396T patent/ES2322992T3/es not_active Expired - Lifetime
- 2003-03-21 CA CA002479881A patent/CA2479881A1/en not_active Abandoned
- 2003-03-21 CN CNA200710308166XA patent/CN101199501A/zh active Pending
- 2003-03-21 CN CNA2007103081674A patent/CN101199512A/zh active Pending
- 2003-03-21 US US10/508,423 patent/US20050227948A1/en not_active Abandoned
- 2003-03-21 CN CNA2007103081706A patent/CN101199503A/zh active Pending
- 2003-03-21 CN CNA2007103081693A patent/CN101199537A/zh active Pending
- 2003-03-21 AT AT03712396T patent/ATE430127T1/de not_active IP Right Cessation
- 2003-03-21 PL PL371515A patent/PL205110B1/pl not_active IP Right Cessation
- 2003-03-21 DE DE60327428T patent/DE60327428D1/de not_active Expired - Lifetime
2006
- 2006-09-11 US US11/518,157 patent/US7662854B2/en not_active Expired - Fee Related
2009
- 2009-06-03 AU AU2009202216A patent/AU2009202216A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20050227948A1 (en)	2005-10-13
CN101199502A (zh)	2008-06-18
CA2479881A1 (en)	2003-10-02
CN1653040A (zh)	2005-08-10
EP2065366A3 (en)	2009-09-02
EP1485347B1 (en)	2009-04-29
WO2003080566A3 (en)	2003-12-11
US20070066576A1 (en)	2007-03-22
CN101199501A (zh)	2008-06-18
MXPA04009155A (es)	2004-11-26
AU2003216857B2 (en)	2009-06-11
CN101199503A (zh)	2008-06-18
EP1485347A2 (en)	2004-12-15
EP2065366A2 (en)	2009-06-03
JP2005520859A (ja)	2005-07-14
AU2003216857A1 (en)	2003-10-08
ES2322992T3 (es)	2009-07-03
PL205110B1 (pl)	2010-03-31
WO2003080566A2 (en)	2003-10-02
AU2009202216A1 (en)	2009-06-25
ATE430127T1 (de)	2009-05-15
CN100369891C (zh)	2008-02-20
DE60327428D1 (de)	2009-06-10
CN101199512A (zh)	2008-06-18
CN101199537A (zh)	2008-06-18
GB0206711D0 (en)	2002-05-01
US7662854B2 (en)	2010-02-16

Legal Events

Date	Code	Title	Description
2012-05-31	LAPS	Decisions on the lapse of the protection rights	Effective date: 20110321

Publication	Publication Date	Title
PL371515A1 (pl)	2005-06-27	Inhibitory hydroksylazy HIF
IS7857A (is)	2005-08-18	Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
IL165257A0 (en)	2005-12-18	11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obestity anddyslipidemia
SI1864975T1 (sl)	2011-01-31	Nikotinamidni derivati, uporabni kot inhibitorji p38
IL174210A0 (en)	2006-08-01	1,4 disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
ZA200706010B (en)	2009-04-29	3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-hetero-ayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
EP1295607A4 (en)	2007-03-28	ANTITUMOR EFFECT AMPLIFIER
EE05417B1 (et)	2011-06-15	Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
IL163911A0 (en)	2005-12-18	Naltrexone hydrochloride compositions
MY135477A (en)	2008-04-30	2-(2,6-dichlorophenyl)-diarylimidazoles
DE60112974D1 (en)	2005-09-29	Carbolinderivate
AU2003227532A1 (en)	2003-09-09	Mononucleotide repeats microsatellite markers for detecting microsatellite instability.
PT2420234E (pt)	2013-10-08	1h-benzimidazole-4-carboxamidas substituídas com um carbono quaternário na posição 2 como inibidores de parp para uso no tratamento do cancro
PT1796660T (pt)	2017-02-13	Utilização de tricloro(dioxietileno-o,o¿)telurato de amónio (as101) para a inibição da enzima de conversão da interleucina-1 beta
DE60216233D1 (en)	2007-01-04	Carbolinderivate
MXPA03009750A (es)	2004-06-30	Compuestos quimicos.
WO2004030671A3 (en)	2004-06-10	Use of 4-amino-quinazolines as anti cancer agents
IL178261A0 (en)	2006-12-31	Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
IL172605A0 (en)	2006-04-10	Aiding of cognitive function
EP1733720A4 (en)	2009-05-06	COMPOSITION WITH THE REDUCED FORM OF COENZYME Q10 AND CAROTENOID COMPOUND
MXPA06003345A (es)	2006-06-08	Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
MXPA06000372A (es)	2006-03-30	Compuestos de silicio y su uso.
TW200508196A (en)	2005-03-01	Hydroxamic acids useful in the treatment of hyper-proliferative disorders
AU2003260723A1 (en)	2004-03-03	Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
AU2003282035A1 (en)	2004-05-04	Modulation of s6 kinase activity for the treatment of obestiy